Skip to content

Author

Mingyao Liu

We have 2 of 14 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Jul 2026

Rewriting CAR-T cell fate: CRISPR/Cas gene editing for solid tumor therapy

Recent advances in the application of CRISPR/Cas gene editing technology to enhance the antitumor activity of CAR-T cells against solid tumors are summarized and the key challenges currently faced are discussed.

Wenjing Liu, Jiayi Gu, Chenghao Xie et al. · 0 citations
Review Aug 2026

The Pharmacology of CAR T Cell Therapy for Autoimmune Disease.

In autoimmune diseases, cell-based therapies exemplified by CAR T cells should be reframed from exposure-control pharmacology to state-transition pharmacology, and through endogenous expansion and immune networks, therapeutic cells may shift the immune system from a pathological toward a tolerant steady state.

Juliang Qin, Guang-Yu Zhang, Ning Zhao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.